Work

Immunotherapy Trials at Children's National Health System Offer Greater Access for Patients of Diverse Backgrounds

Year: 2019

Type: article

Abstract: is needed to determine outcomes after receiving CAR-T immunotherapy, especially to track significant adverse events, including potentially cytokine release syndrome, neurologic complications and kidney/liver failure.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2018.12.547

Authors: Patrick J. Hanley, Barbara O'Brien, Jamie Hoover, Fahmida Hoq, Michael D. Keller, Kirsten M. Williams, Allistair Abraham, Lauren P. McLaughlin, Holly Meany, Jay Tanna, Nan Zhang, Catherine M. Bollard

Institution: Children's National

Language: English

Topic: Ethics in Clinical Research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,650

OpenAlex ID: W2912928949

FWCI:

Cites:

Cited by:

Related to: 10